Chapter 4 The Capsule of the Fungal Pathogen Cryptococcus neoformans

https://doi.org/10.1016/S0065-2164(09)01204-0Get rights and content

Abstract

The capsule of the fungal pathogen Cryptococcus neoformans has been studied extensively in recent decades and a large body of information is now available to the scientific community. Well‐known aspects of the capsule include its structure, antigenic properties and its function as a virulence factor. The capsule is composed primarily of two polysaccharides, glucuronoxylomannan (GXM) and galactoxylomannan (GalXM), in addition to a smaller proportion of mannoproteins (MPs). Most of the studies on the composition of the capsule have focused on GXM, which comprises more than 90% of the capsule's polysaccharide mass. It is GalXM, however, that is of particular scientific interest because of its immunological properties. The molecular structure of these polysaccharides is very complex and has not yet been fully elucidated. Both GXM and GalXM are high molecular mass polymers with the mass of GXM equaling roughly 10 times that of GalXM. Recent findings suggest, however, that the actual molecular weight might be different to what it has traditionally been thought to be. In addition to their structural roles in the polysaccharide capsule, these molecules have been associated with many deleterious effects on the immune response. Capsular components are therefore considered key virulence determinants in C. neoformans, which has motivated their use in vaccines and made them targets for monoclonal antibody treatments. In this review, we will provide an update on the current knowledge of the C. neoformans capsule, covering aspects related to its structure, synthesis and particularly, its role as a virulence factor.

Introduction

The adaptation of microorganisms to their environment is often associated with the acquisition of certain attributes that help improve survival in specific ecological niches. Such adaptations include signal transduction pathways that optimize metabolism to respond to the nutritional environment, stress conditions and interaction with other biological systems, such as other microbes, environmental predators and symbiotic hosts. In addition, it is common to find morphological changes and the development of specialized structures that provide the microbe with survival benefits during its life cycle. Among these structures, many microbes possess capsules surrounding their cell body. Microbial capsules are usually composed of polysaccharides although some organisms, like Bacillus anthracis, have capsules composed of polymerized d‐glutamic acids. Microbial capsules play important roles in the lives of these microorganisms, providing resistance to stressful conditions (such as dehydration) and playing a key role in the interaction with the environment.

Although capsules are commonly found among bacteria, there are a few encapsulated fungal species. The best characterized fungal capsule belongs to Cryptococcus neoformans. The capsule of this microorganism has been extensively studied because it is the main virulence factor of this pathogenic organism (McClelland et al., 2006). In the environment, the capsule plays a role in the protection of the organism against some stress conditions, such as dehydration (Aksenov et al., 1973). The C. neoformans capsule has some functional similarities to those of encapsulated bacteria such as, Streptococcus pneumoniae and Haemophilus influenzae (De Jesus et al., 2008, Kang et al., 2004). In fact, the cryptococcal polysaccharide is known to share some antigenic determinants with certain pneumococcal polysaccharides (Maitta et al., 2004b, Pirofski and Casadevall, 1996). The capsule is important for virulence, since acapsular mutants do not produce disease in murine models (Fromtling et al., 1982). The definitive experiment establishing the capsule as a virulence factor was accomplished when acapsular mutants were created and shown to be significantly less virulent than wild‐type or capsule‐reconstituted strains (Chang and Kwon‐Chung, 1994). These mutants can survive and replicate in normal laboratory conditions but exhibit a markedly reduced virulence during infection in murine models. Interestingly, acapsular strains can be pathogenic for severely immunocompromised hosts implying a residual pathogenic potential for nonencapsulated yeast cells (Salkowski and Balish, 1991). These studies established that the capsule plays a predominant role in the interaction with the host. Consequently, this structure has been the main focus of attention in many experimental studies. Furthermore, studies have also shown that the capsular polysaccharide has strong immunomodulatory properties and promotes immune evasion and survival within the host (Monari et al., 2006a, Vecchiarelli, 2000). Besides mammalian hosts, studies focused on the capsule have also been extended to include environmental predators such as amoebae, since C. neoformans is both a pathogen and an environmental yeast and therefore interacts with multiple types of hosts.

A vast amount of knowledge has been accumulated on the biology, structure and role of the capsule during infection. The purpose of this review is to give an overview on the main aspects of the capsule, including its structure, synthesis and in particular, its role as a virulence factor.

Section snippets

Capsule Components and Structure

The most characteristic feature of C. neoformans is a polysaccharide capsule that surrounds the cell body. The capsule is not visible by regular microscopy because it is highly hydrophilic and due to its high water content it has the same refraction index as the medium. However, it can be easily made visible by several techniques. The classic image of the capsule is that of a halo surrounding the cell made visible by suspending the yeast in India ink preparations. The halo effect is a

The CAP genes

During the last decade, different genes involved in capsule biosynthesis have been identified. The first one, CAP59, was cloned by complementation of an acapsular mutant isolated by UV random mutagenesis (Chang and Kwon‐Chung, 1994). The gene was deleted by homologous recombination and resulted in an acapsular phenotype associated with loss of virulence in an animal model of cryptococcal infection. The restoration of virulence by complementation of the acapsular phenotype represented the first

Capsule Functions in C. neoformans: The Capsule as a Virulence Factor: Function During the Interaction with the Host

C. neoformans virulence is a complex process and there is evidence that both fungal components and the immune response to infection combine to damage the host (Casadevall and Pirofski, 2003). Concerning fungal factors, the capsule is the major virulence factor involved in the pathogenesis. As stated previously, the polysaccharide from the capsule can be found attached to the cell forming the physical structure and released to the medium, as exopolysaccharide. Multiple studies indicate that both

Use of Capsular Components as Antifungal Targets and Vaccine

Given the critical role of the capsule in virulence, considerable efforts have been undertaken to develop antibodies and vaccines that target this structure. Two general approaches have been taken. First, many mAbs have been developed with the purpose of targeting the capsular components, as a passive immunization. Studies with these mAbs have shown that antibody function against C. neoformans is extremely complex in the sense that some immunoglobulins confer protection, while others do not and

Future Perspectives

After 50 years of intensive study that has included serological, biochemical, immunological, microscopic, genetic and physical investigations, much is known about the C. neoformans capsule. The capsule is widely acknowledged to be an indispensable virulence factor and continues to occupy much of the investigative attentions of the cryptococcal field. However, despite hundreds of publications detailing capsule‐related studies, the capsule remains an enigmatic structure that continues to defy

Acknowledgments

We are indebted to Karen Dente for the outstanding review and editing of the manuscript. O.Z. is a “Ramón y Cajal” fellow and is supported by grants 1025/06 and 1142/08 from MICINN and 1181/06 from Instituto de Salud Carlos III. A.C. is supported by NIH grants AI033774, HL059842 and 5R37AI033142. E.D. is supported by NIH grant AI60507.

References (347)

  • S.I. Aksenov et al.

    On the mechanism of adaptation of micro‐organisms to conditions of extreme low humidity

    Life. Sci. Space Res.

    (1973)
  • J.A. Alspaugh et al.

    Cryptococcus neoformans mating and virulence are regulated by the G‐protein alpha subunit GPA1 and camp

    Genes Dev.

    (1997)
  • J.A. Alspaugh et al.

    Adenylyl cyclase functions downstream of the Galpha protein Gpa1 and controls mating and pathogenicity of Cryptococcus neoformans

    Eukaryot. Cell

    (2002)
  • M. Alvarez et al.

    Cell‐to‐cell spread and massive vacuole formation after Cryptococcus neoformans infection of murine macrophages

    BMC Immunol.

    (2007)
  • Y. Apidianakis et al.

    Challenge of Drosophila melanogaster with Cryptococcus neoformans and role of the innate immune response

    Eukaryot. Cell

    (2004)
  • Y.S. Bahn et al.

    Adenylyl cyclase‐associated protein Aca1 regulates virulence and differentiation of Cryptococcus neoformans via the cyclic AMP‐protein kinase A cascade

    Eukaryot. Cell

    (2004)
  • Y.S. Bahn et al.

    Specialization of the HOG pathway and its impact on differentiation and virulence of Cryptococcus neoformans

    Mol. Biol. Cell

    (2005)
  • R.D. Baker et al.

    Tissue changes and tissue diagnosis in cryptococcosis; a study of 26 cases

    Am. J. Clin. Pathol.

    (1955)
  • L.G. Baker et al.

    Chitosan, the deacetylated form of chitin, is necessary for cell wall integrity in Cryptococcus neoformans

    Eukaryot. Cell

    (2007)
  • I.R. Banks et al.

    A chitin synthase and its regulator protein are critical for chitosan production and growth of the fungal pathogen Cryptococcus neoformans

    Eukaryot. Cell

    (2005)
  • F.M. Barbosa et al.

    Binding of glucuronoxylomannan to the CD14 receptor in human A549 alveolar cells induces interleukin‐8 production

    Clin. Vaccine Immunol.

    (2007)
  • R. Barluzzi et al.

    Role of the capsule in microglial cell–Cryptococcus neoformans interaction: Impairment of antifungal activity but not of secretory functions

    Med. Mycol.

    (1998)
  • M. Bar‐Peled et al.

    Functional cloning and characterization of a UDP‐glucuronic acid decarboxylase: The pathogenic fungus Cryptococcus neoformans elucidates UDP‐xylose synthesis

    Proc. Natl. Acad. Sci. USA

    (2001)
  • M. Bar‐Peled et al.

    Biosynthesis of UDP‐glca, a key metabolite for capsular polysaccharide synthesis in the pathogenic fungus Cryptococcus neoformans

    Biochem. J.

    (2004)
  • D.O. Beenhouwer et al.

    Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans

    Infect. Immun.

    (2001)
  • D.O. Beenhouwer et al.

    Human immunoglobulin G2 (igg2) and igg4, but not igg1 or igg3, protect mice against Cryptococcus neoformans infection

    Infect. Immun.

    (2007)
  • T. Belay et al.

    Reactivity patterns and epitope specificities of anti‐Cryptococcus neoformans monoclonal antibodies by enzyme‐linked immunosorbent assay and dot enzyme assay

    Infect. Immun.

    (1997)
  • C. Biondo et al.

    Characterization of two novel cryptococcal mannoproteins recognized by immune sera

    Infect. Immun.

    (2005)
  • R. Blackstock

    Cryptococcal capsular polysaccharide utilizes an antigen‐presenting cell to induce a T‐suppressor cell to secrete tsf

    J. Med. Vet. Mycol.

    (1996)
  • R. Blackstock

    Roles for CD40, B7 and major histocompatibility complex in induction of enhanced immunity by cryptococcal polysaccharide‐pulsed antigen‐presenting cells

    Immunology

    (2003)
  • R. Blackstock et al.

    Presentation of cryptococcal capsular polysaccharide (GXM) on activated antigen‐presenting cells inhibits the T‐suppressor response and enhances delayed‐type hypersensitivity and survival

    Immunology

    (1997)
  • R. Blackstock et al.

    Non‐specific immunosuppression by Cryptococcus neoformans infection

    Mycopathologia

    (1984)
  • R. Blackstock et al.

    Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans

    Infect. Immun.

    (1997)
  • R. Blackstock et al.

    Induction of a macrophage‐suppressive lymphokine by soluble cryptococcal antigens and its association with models of immunologic tolerance

    Infect. Immun.

    (1987)
  • R. Blackstock et al.

    Differential regulation of immune responses by highly and weakly virulent Cryptococcus neoformans isolates

    Infect. Immun.

    (1999)
  • R. Blackstock et al.

    Regulation of cytokine expression in mice immunized with cryptococcal polysaccharide, a glucuronoxylomannan (GXM), associated with peritoneal antigen‐presenting cells (APC): Requirements for GXM, APC activation and interleukin‐12

    Infect. Immun.

    (2000)
  • I. Bose et al.

    A yeast under cover: The capsule of Cryptococcus neoformans

    Eukaryot. Cell

    (2003)
  • R.A. Bryan et al.

    Radiological studies reveal radial differences in the architecture of the polysaccharide capsule of Cryptococcus neoformans

    Eukaryot. Cell

    (2005)
  • L.A. Bunting et al.

    Cryptococcus neoformans: Gastronomic delight of a soil ameba

    Sabouraudia

    (1979)
  • M.A. Campos et al.

    Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides

    Infect. Immun.

    (2004)
  • A. Casadevall et al.
  • A. Casadevall et al.

    The damage‐response framework of microbial pathogenesis

    Nat. Rev. Microbiol.

    (2003)
  • A. Casadevall et al.

    Accidental virulence, cryptic pathogenesis, martians, lost hosts and the pathogenicity of environmental microbes

    Eukaryot. Cell

    (2007)
  • A. Casadevall et al.

    Antibodies elicited by a Cryptococcus neoformans–tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection

    J. Infect. Dis.

    (1992)
  • A. Casadevall et al.

    Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan

    Infect. Immun.

    (1994)
  • A. Castellani

    Phagocytic and destructive action of Hartmanella castellanii (Amoeba castellanii) on pathogenic encapsulated yeast‐like fungi Torulopsis neoformans (Cryptococcus neoformans)

    Ann. Inst. Pasteur (Paris)

    (1955)
  • S.A. Castle et al.

    The {beta}1,2‐xylosyltransferase Cxt1p is solely responsible for xylose incorporation into Cryptococcus neoformans glycosphingolipids

    Eukaryot. Cell

    (2008)
  • L.K. Cauley et al.

    Response of congenitally athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection

    Infect. Immun.

    (1979)
  • W. Chaka et al.

    Induction of TNF‐alpha in human peripheral blood mononuclear cells by the mannoprotein of Cryptococcus neoformans involves human mannose binding protein

    J. Immunol.

    (1997)
  • W. Chaka et al.

    Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells

    Infect. Immun.

    (1997)
  • Cited by (344)

    • Cryptococcus neoformans: life cycle, morphogenesis, and virulence

      2023, Molecular Medical Microbiology, Third Edition
    View all citing articles on Scopus
    View full text